Study guide

16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea

AMCB Certified Nurse-Midwife CNM

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care

1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral

2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts

2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy

3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy

3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy

4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss

4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care

5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance

5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion

6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation

6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy

7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair

7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture

8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation

8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications

9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage

9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation

10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health

10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis

11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination

11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes

12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days

12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days

13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization

13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening

14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation

14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral

15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders

15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome

16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause

16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis

17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions

17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking

18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity

18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care

16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea

Key Takeaways Explain This Topic AI

Up to 70 to 80 percent of women with chlamydia are asymptomatic, which is why annual screening of all sexually active women under 25 is universal.

First-line chlamydia treatment in non-pregnant patients is doxycycline 100 mg twice daily for 7 days, which outperformed single-dose azithromycin in trials.

NAAT on a self-collected or clinician-collected vaginal swab has the highest sensitivity for chlamydia and gonorrhea.

Complicated vulvovaginal candidiasis, including recurrent, severe, non-albicans, or immunocompromised cases, requires extended therapy rather than a single fluconazole dose.

Trichomoniasis is sexually transmitted and requires partner treatment and re-screening, and CDC now prefers multi-dose metronidazole for women over the single 2 g dose.

Last updated: September 2026

Vulvovaginal Candidiasis: Clinical Classification & Treatment

Vulvovaginal Candidiasis (VVC) results from symptomatic fungal overgrowth within the vaginal vault. Over 75% of women experience at least one lifetime episode, and 40% to 45% experience two or more.

Classification: Uncomplicated vs. Complicated

Uncomplicated VVC (90%): Sporadic, infrequent episodes (<4 per year); mild-to-moderate symptoms; suspected Candida albicans ; immunocompetent non-pregnant host.

Treatment: Single-dose Fluconazole 150 mg PO ; OR short-course topical azoles (Clotrimazole, Miconazole, or Terconazole cream/suppositories for 1 to 7 days).

Complicated VVC: Recurrent VVC (RVVC), severe edema/fissuring, non-albicans species ( Candida glabrata ), or occurring in compromised hosts (uncontrolled diabetes, immunosuppression, pregnancy).

Recurrent VVC (RVVC): Defined as ≥4 microbiologically confirmed episodes within 12 months .

RVVC Regimen: Induction therapy with Fluconazole 150 mg PO every 72 hours for 3 doses (Days 1, 4, and 7), followed by maintenance suppressive therapy with Fluconazole 150 mg PO once weekly for 6 months .

Non-Albicans Infection (Candida glabrata): Frequently resistant to azoles. First-line therapy is topical Boric Acid 600 mg in a gelatin capsule inserted intravaginally daily at bedtime for 14 to 21 days. Warning: Boric acid is fatal if ingested orally and is strictly contraindicated during pregnancy!

Caution

Pregnancy Warning on Oral Fluconazole: Oral fluconazole is CONTRAINDICATED in pregnancy due to epidemiological and pharmacokinetic data demonstrating an increased risk of spontaneous abortion, as well as congenital craniofacial and cardiac malformations associated with first-trimester exposure. During pregnancy, ONLY topical azole therapies (e.g., Clotrimazole 1% or 2% vaginal cream, or Miconazole vaginal cream for 7 consecutive days) may be prescribed!

Trichomoniasis: Parasitology, Diagnosis & CDC Updates

Trichomonas vaginalis is an obligate, flagellated parasitic protozoan that infects the squamous epithelium of the lower urogenital tract. It is exclusively transmitted through sexual intercourse.

Clinical Presentation: Copious, malodorous, frothy yellow-green discharge with severe vulvar pruritus, dyspareunia, and postcoital bleeding. Classic physical exam finding: Colpitis macularis ("strawberry cervix") , characterized by prominent micro-petechiae across the ectocervix, visible in up to 45% of cases on colposcopy.

Diagnostic Modalities:

Saline Wet Mount: Direct visualization of live, motile, oval-to-pear-shaped trichomonads displaying rapid, jerky, undulating flagellar movement alongside abundant polymorphic leukocytes. Wet mount sensitivity is poor (50% to 60%) because trichomonads rapidly lose motility once removed from the body.

Nucleic Acid Amplification Testing (NAAT): The gold-standard diagnostic modality (sensitivity and specificity >95% to 100%). FDA-cleared NAATs (Aptima, BD MAX) using vaginal, endocervical, or urine specimens are recommended for all symptomatic women and high-risk screening.

CDC Treatment Guidelines (Updated):

Preferred Regimen for Women: Metronidazole 500 mg PO BID for 7 days . Randomized controlled trials demonstrated that the 7-day multidose regimen achieves a 50% lower treatment failure rate compared to the historical single 2 g dose.

Alternative Regimen: Tinidazole 2 g PO in a single dose.

Pregnancy: Metronidazole 500 mg PO BID for 7 days is safe and recommended in all trimesters of pregnancy.

Mandatory Partner Management: Both sexual partners must be treated simultaneously. Patients must strictly abstain from sexual intercourse until both partners have completed therapy and symptoms have completely resolved. Expedited Partner Therapy (EPT) should be provided where permitted by state law.

Rescreening Requirement: Mandatory repeat screening with NAAT 3 months post-treatment due to high reinfection rates (up to 17%).

  • Sexually Transmitted Bacterial Infections: Chlamydia & Gonorrhea
  • Chlamydia trachomatis

Chlamydia trachomatis is an obligate intracellular bacterium and the most commonly reported bacterial STI in the United States. Up to 70% to 80% of women are entirely asymptomatic , serving as an unrecognized reservoir for ascending infection.

Clinical Features: Endocervical mucopurulent discharge, cervical friability (contact bleeding during Pap or swab collection), postcoital bleeding, dysuria, and pyuria.

Screening Imperatives: Annual universal screening for all sexually active women aged <25 years , and women aged ≥25 years with new/multiple partners or inconsistent barrier use. Universal first-trimester prenatal screening with repeat third-trimester screening for high-risk individuals.

Diagnostic Gold Standard: NAAT on first-catch urine, self-collected or clinician-collected vaginal swab (highest sensitivity), or endocervical swab.

CDC Treatment Guidelines (Updated):

First-Line Regimen (Non-Pregnant): Doxycycline 100 mg PO BID for 7 days . Clinical trials demonstrated doxycycline's clear superiority over single-dose azithromycin, particularly for concurrent rectal chlamydial infection (microbial cure 97% vs. 74%).

First-Line Regimen in Pregnancy: Azithromycin 1 g PO in a single dose . (Doxycycline is strictly contraindicated during pregnancy due to fetal hepatotoxicity, permanent tooth discoloration, and inhibition of long-bone growth).

Alternative in Pregnancy: Amoxicillin 500 mg PO TID for 7 days.

Follow-Up & Test-of-Cure (TOC):

In non-pregnant individuals treated with first-line doxycycline, a test-of-cure is not recommended unless therapeutic compliance is questioned or symptoms persist. Rescreening with NAAT is mandatory at 3 months to detect reinfection.

In pregnant individuals , a Test-of-Cure (TOC) via NAAT is MANDATORY 4 weeks after treatment completion , followed by repeat screening in the third trimester.

Neisseria gonorrhoeae

Neisseria gonorrhoeae is a fastidious, Gram-negative intracellular diplococcus that infects mucosal columnar and transitional epithelium. Co-infection with C. trachomatis occurs in up to 30% to 40% of cases.

Clinical Presentation: Copious, thick, green-yellow purulent endocervical discharge, severe dysuria, intermenstrual bleeding, labial pain, and Bartholin's or Skene's gland abscesses.

CDC Treatment Guidelines (Weight-Based Monotherapy):

Weight <150 kg (330 lbs): Ceftriaxone 500 mg IM in a single dose .

Weight ≥150 kg (330 lbs): Ceftriaxone 1 g (1,000 mg) IM in a single dose .

Rule on Co-Infection: If chlamydial infection has NOT been excluded by NAAT , clinicians must add Doxycycline 100 mg PO BID for 7 days (or Azithromycin 1 g PO in pregnancy).

Severe Cephalosporin Allergy: Gentamicin 240 mg IM single dose PLUS Azithromycin 2 g PO single dose.

Follow-Up: Retest with NAAT at 3 months . A test-of-cure at 7 to 14 days is required only for pharyngeal gonorrhea treated with an alternative regimen.